SupportLoginSign Up
Featured FeedJournalsCollectionsKeywords
RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

Long term effects of long chain polyunsaturated fats in hyperphenylalaninemic children.

C Agostoni, E Verduci, N Massetto, L Fiori, G Radaelli, E Riva, M Giovannini
Archives of Disease in Childhood 2003 July
Blood fatty acid status and visual function of 20 treated hyperphenylalaninemic (HPA) children, randomly allocated into two groups to receive supplementation of either long chain polyunsaturated fatty acids (LCPUFA), including docosahexaenoic acid (DHA), or placebo for 12 months, have been investigated three years after the end of the treatment. Although in the LCPUFA group blood DHA levels and P100 wave latency improved at the end of supplementation, they had returned to baseline after three years.

Full text links

Find Full Text Links for this Article

Trending Papers

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors.Joshua J Neumiller et al.TouchREVIEWS in endocrinology. 2022 November
Management of Latent Tuberculosis Infection.Steven Kim, Rebecca Thal, Daria SzkwarkoJAMA 2023 January 20
The Difficult Airway Redefined.Matthew B Burgess et al.Prehospital and Disaster Medicine 2022 November 10
Inappropriate Use of Proton Pump Inhibitors Increases Cardiovascular Events in Patients with Coronary Heart Disease.Wen Hu, Yunhao Luo, Xiujuan YangInternational Journal of General Medicine 2022
Misdiagnosis in the Emergency Department: Time for a System Solution.Jonathan A Edlow, Peter J PronovostJAMA 2023 January 28
Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension.Nathan I Shapiro et al.New England Journal of Medicine 2023 January 22

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app